Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chagas disease drug development
ISRCTN26467068Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Jun 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in American trypanosomiasis (CD) comparing Benznidazole arm, Nifurtimox arm and Posaconazole arm (3 arms). Primary endpoints: Temporal fluctuation pattern of blood-stage parasite density, Parasite clearance half-life in blood and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
benznidazolenifurtimoxposaconazole
03
Conditions
American trypanosomiasis (CD)
Beyond the preview
Go deeper on ISRCTN26467068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN26467068.